Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (<scp>pEGPA</scp>)-Reference-Cited by-同舟云学术

Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA)

Published:2023-05-17 Issue:3 Volume:64 Page:404-407
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Bandla M.¹^ORCID,Howard M.²^ORCID,McNally A.²,Armstrong D.³,Simpson I.⁴,Mar A.²

Affiliation:

1. Monash Medical Centre Clayton Victoria Australia

2. Department of Dermatology, Monash Medical Centre, Monash Health Clayton Victoria Australia

3. Department of Respiratory and Sleep Medicine, Monash Medical Centre, Monash Health Victoria Clayton Australia

4. Department of Pathology, Monash Medical Centre, Monash Health Clayton Victoria Australia

Abstract

AbstractEosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis presenting primarily with pulmonary and cutaneous features. The disease is typically seen in the fifth or sixth decade of life (1, 2). We report a case of EGPA in an adolescent who was successfully treated with the interleukin‐5 (IL‐5) receptor inhibitor, benralizumab.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14081

Reference11 articles.

1. Churg–Strauss syndrome

2. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

3. Cutaneous manifestations of childhood Eosinophilic Granulomatosis with Polyangiitis (cEGPA): A case‐based review

4. Churg-Strauss Syndrome Clinical Study and Long-Term Follow-Up of 96 Patients

5. Eosinophilic Granulomatosis with Polyangiitis: An Overview

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan;Drugs;2024-06